Editorial: State-of-the-art research on C1q and the classical complement pathway by Kishore, U et al.
October 2016 | Volume 7 | Article 3981
Editorial
published: 04 October 2016
doi: 10.3389/fimmu.2016.00398
Frontiers in Immunology | www.frontiersin.org
Edited and Reviewed by: 
Francesca Granucci, 
University of Milano-Bicocca, Italy
*Correspondence:
Uday Kishore  
uday.kishore@brunel.ac.uk, 
ukishore@hotmail.com; 
Nicole M. Thielens  
nicole.thielens@ibs.fr
Specialty section: 
This article was submitted to 
Molecular Innate Immunity, 
a section of the journal 
Frontiers in Immunology
Received: 26 August 2016
Accepted: 20 September 2016
Published: 04 October 2016
Citation: 
Kishore U, Thielens NM and 
Gaboriaud C (2016) Editorial: 
State-of-the-Art Research on 
C1q and the Classical 
Complement Pathway. 
Front. Immunol. 7:398. 
doi: 10.3389/fimmu.2016.00398
Editorial: State-of-the-art research 
on C1q and the Classical 
Complement Pathway
Uday Kishore1*, Nicole M. Thielens2* and Christine Gaboriaud2
1 College of Health and Life Sciences, Brunel University London, Uxbridge, UK, 2 Institut de Biologie Structurale (IBS), 
Université Grenoble Alpes, CEA, CNRS, Grenoble, France
Keywords: complement, C1 complex, C1q, gC1q structure, C1s, classical pathway activation, autoimmunity, 
emerging functions
The Editorial on the Research Topic
State-of-the-Art Research on C1q and the Classical Complement Pathway
Complement protein C1q is a fascinating innate immune molecule. C1q is the first subcomponent 
of the classical complement pathway. Its primary three-chain structure (A, B, and C chains), which 
is composed of a triple-helical collagen-like region and a C-terminal ligand-recognizing globular 
head (gC1q) domain, yields a tulip-like organization with six gC1q domains, each representing a het-
erotrimer (the C-terminal regions of the A, B, and C chains) (1). In addition to binding to immune 
complexes containing IgG and IgM, the gC1q domain also engages with a number of self and non-self 
ligands. A summary of the structural basis of C1q–ligand interactions has been elegantly presented 
in the review by Gaboriaud et al. For example, it shows that C1q can recognize multiple ligands on 
the apoptotic cell surface, which illustrates its versatile surface recognition properties. A common 
binding area for several of these non-immune ligands has been observed in the subunit C, which 
could play a role in restricting the activation of the classical complement pathway.
It has become evident over the course of the last two decades that the gC1q domain is widely 
conserved across a diverse range of vertebrate and invertebrate proteins (2). The functions of these 
proteins can range from being immunological to structural. Through a review article, Ghebrehiwet 
et al. have cited two examples of C1q functions that are distinct from its involvement in the classical 
pathway: its ability to induce apoptosis in prostate cancer cells, and to modulate vascularization for 
fetal–maternal interaction. Given the existence of a C1q–TNF superfamily based on the remarkable 
structural similarities between C1q and TNF family members (1), a good argument has been made 
for a cytokine-like property of C1q. The complexity and diversity related to the functions of C1q 
family have been greatly exemplified by a structure–function review article by Colombatti et al., 
who describe the functions associated with the gC1q domain of two C1q family members – such as 
EMILIN and multimerin. A slight structural variation from the prototypical structure, as revealed by 
the NMR solution structure, is insightful, purporting one residue in the interaction of gC1q domain 
with α4β1 and α9β1 integrins.
In recent years, a number of functions of C1q have emerged that are complement independent. 
This is reflected in the local synthesis of C1q by various immune and non-immune cells. The diversity 
of C1q functions includes its involvement in dendritic cell maturation, immune modulation, cell 
differentiation, cancer progression, neuronal synapse pruning, and pregnancy. This has been exten-
sively summarized by Kouser et al. In the backdrop of a recent observation that C1q gene knockout 
mice show nearly all features of preeclampsia, the role of C1q in normal and complicated pregnancies 
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has become a burning issue in the reproductive immunology. In 
this issue, Madhukaran et al. have reported a link between the 
expression of the transcription factor PU.1 and C1q in human 
trophoblasts and stromal cells, similar to DCs and macrophages, 
using early decidual tissue.
Given its involvement in a wide range of homeostatic func-
tions, it is not surprising that C1q is central to many human 
diseases. C1q, as a key molecule in self-tolerance mechanisms, 
is involved in clearing immune complexes and apoptotic/
necrotic cells. C1q-deficient mice have been shown to have 
lupus-like symptoms. However, this issue is further confounded 
by the fact that anti-C1q autoantibodies are found in a number 
of pathological situations, more so in systemic lupus erythe-
matosus (SLE). These autoantibodies are certainly required 
for the development of lupus nephritis. Since C1q itself is an 
IgG-binding protein, identification and characterization of 
anti-C1q autoantibodies is a challenging task. Mahler et al. have 
addressed the technicalities of this endeavor, while reassessing 
the pathological consequences of such autoantibodies in a dis-
ease context. In line with the involvement of C1q in tolerance 
and SLE, Ghebrehiwet et  al. have addressed the importance 
of monocyte surface expressed C1q in association with C1r 
and C1s. This review examines the role of cell-bound C1q in 
capturing and processing circulating immune complexes and 
pathogen-associated molecular patterns (PAMPs). The ability 
of C1q to modulate PAMP-recognizing receptors (PRRs) makes 
it a potent and versatile immune surveillance molecule of the 
innate immunity.
The final section of the issue is dedicated to the understanding 
of the mechanisms underlying activation of the classical pathway 
and their specific inhibition for therapeutic purposes.
In an original research article, Wijeyewickrema et al. aim at 
further deciphering the interaction of the C1s protease with its 
C4 protein substrate. Previous studies had provided evidence 
for homologous C4 interaction exosites in the CCP and serine 
protease domains of both C1s and MASP-2 (3). The authors focus 
here on the role of C1s Lys628 residue of the serine protease 
domain. Using site-directed mutagenesis and a peptide substrate 
library, they show that this residue plays a different role in cleaving 
peptide versus protein substrates by interacting with C4 in order 
to facilitate its cleavage. The architecture of the active site at this 
position is markedly different in C1s compared with MASP-2 (4), 
which might provide clues toward designing specific inhibitors of 
the classical pathway.
In a review article, Sharp et al. focus on complement inhibitors 
of the classical pathway for application in transfusion medicine. 
Uncontrolled antibody-initiated complement activation plays 
a central role in hemolytic diseases such as acute intravascular 
hemolytic transfusion reaction (AIHTR). The authors have 
identified peptide inhibitors of C1 (PIC1) derived from a region 
of the coat protein of astrovirus with homology to human neu-
trophil peptide 1 that inhibits complement activation by binding 
to the collagen-like regions of C1q (5). They have developed a 
simple rat model of AIHTR for future preclinical studies of PIC1. 
A review of complement inhibitors, marketed as well as currently 
under development, is presented, and their therapeutic potential 
in transfusion and blood disorders is discussed.
In their perspective article, Gaboriaud et  al. provide an 
update on the current knowledge about the structural basis of 
the mechanisms involved in the assembly and activation of the 
C1 complex. The main protein players involved in C1 activation 
and its control are presented together with the molecular dis-
section strategy used to define structure–function relationships 
of C1 subcomponents and to decipher key protein–protein 
interactions. However, the conformational changes required 
for allowing C1 activation following target binding are still not 
elucidated, and this is one among 16 still unanswered questions 
identified by the authors. Hopefully, new technological devel-
opments in structural biology, such as a combination of X-ray 
crystallography and electron microscopy, will help fulfilling this 
“mission impossible.”
This special topic issues clearly highlights the diversity and 
complexity associated with structures and functions of C1q and 
C1q family members. We have come a long way in understand-
ing the structural basis of the gC1q interaction with self and 
non-self ligands. While additional members of C1q family are 
still being identified and characterized, the importance of the 
gC1q domain in the evolutionary history of animals is unique. 
From being a prototypical innate immune molecule, C1q is 
now regarded as an independent modulator of a diverse range 
of functions that are not dependent on its involvement in the 
complement activation. These complement-independent func-
tions of C1q are likely to be the major thrust of research in 
coming years.
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